priority health glp-1 coverage Medicare Drug The GLP-1 Access Gap: Mapping

Novo Nordisk and Ascendis Pharma have partnered to develop a long-acting, monthly GLP-1 drug

By Amina Niasse NEW YORK, June 2 (Reuters) - Health insurer Cigna will stop covering GLP-1 weight-loss drugs including Novo Nordisk's Wegovy and Eli Lilly's Zepbound in its employee health plan

Lets take a closer look at how these medications work, their benefits and their drawbacks.

Insurers raised cost-sharing sharply for GLP-1s in recent years and also increased use of prior authorization.

SUPPORTS GLP-1 PRODUCTION These compounds help stimulate natural GLP-1 release, leading to better appetite control and improved insulin sensitivity